Related Experiment Video
Updated: Feb 15, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Long Non-Coding RNAs in Multiple Myeloma
Lucia Nobili1, Domenica Ronchetti2, Luca Agnelli3
1Department of Oncology and Hemato-Oncology, University of Milan, and Hematology, Fondazione Ca' Granda IRCCS Policlinico, 20122 Milan, Italy. lucia.nobili@unim.it.
Abstract:
Multiple myeloma (MM) is an incurable disease caused by the malignant proliferation of bone marrow plasma cells, whose pathogenesis remains largely unknown. Although a large fraction of the genome is actively transcribed, most of the transcripts do not serve as templates for proteins and are referred to as non-coding RNAs (ncRNAs), broadly divided into short and long transcripts on the basis of a 200-nucleotide threshold. Short ncRNAs, especially microRNAs, have crucial roles in virtually all types of cancer, including MM, and have gained importance in cancer diagnosis and prognosis, predicting the response to therapy and, notably, as innovative therapeutic targets. Long ncRNAs (lncRNAs) are a very heterogeneous group, involved in many physiological cellular and genomic processes as well as in carcinogenesis, cancer metastasis, and invasion. LncRNAs are aberrantly expressed in various types of cancers, including hematological malignancies, showing either oncogenic or tumor suppressive functions. However, the mechanisms of the related disease-causing events are not yet revealed in most cases. Besides emerging as key players in cancer initiation and progression, lncRNAs own many interesting features as biomarkers with diagnostic and prognostic importance and, possibly, for their utility in therapeutic terms as druggable molecules. This review focuses on the role of lncRNAs in the pathogenesis of MM and summarizes the recent literature.
Insights
Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in multiple myeloma (MM) pathogenesis. This review explores lncRNAs
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Multiple myeloma (MM) is an incurable plasma cell malignancy with largely unknown pathogenesis.
- Non-coding RNAs (ncRNAs), including microRNAs and long non-coding RNAs (lncRNAs), play critical roles in cancer.
- lncRNAs are involved in cellular processes and carcinogenesis, with aberrant expression observed in hematological malignancies.
Purpose of the Study:
- To review the current literature on the role of long non-coding RNAs (lncRNAs) in the pathogenesis of multiple myeloma (MM).
- To highlight the potential of lncRNAs as diagnostic, prognostic, and therapeutic targets in MM.
Main Methods:
- Literature review of recent studies on lncRNAs and multiple myeloma.
- Analysis of lncRNA expression patterns and functional roles in MM pathogenesis.
- Summary of lncRNAs' potential as biomarkers and therapeutic agents.
Main Results:
- lncRNAs are aberrantly expressed in MM and can function as oncogenes or tumor suppressors.
- Mechanisms underlying lncRNA involvement in MM pathogenesis are under investigation.
- lncRNAs show promise as biomarkers for MM diagnosis and prognosis.
Conclusions:
- lncRNAs are key players in MM initiation and progression.
- Further research into lncRNA mechanisms is crucial for understanding MM.
- lncRNAs represent promising targets for novel MM diagnostics and therapeutics.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
piRNA - Piwi-interacting RNAs
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
Nursing Code of Ethics

